Dianthus Therapeutics, Inc.

DNTH

US2528281080

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:19:29 2024-05-09 pm EDT			5-day change	1st Jan Change
25.04 ^USD	+5.14%		+5.68%	+128.94%

Apr. 11	Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc	CI
Mar. 22	Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating	MT

Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc

April 11, 2024 at 04:06 pm EDT

Dianthus Therapeutics, Inc. announced that Lei Meng, a current Class III Director, will not stand for reelection at the Annual Meeting.

Latest news about Dianthus Therapeutics, Inc.

Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc	Apr. 11	CI
Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating	Mar. 22	MT
Dianthus Therapeutics, Inc. Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis	Feb. 26	CI
Stifel Initiates Dianthus Therapeutics With Buy Rating, $44 Price Target	Feb. 15	MT
Wedbush Lifts Dianthus Therapeutics' PT to $24 From $23, Updates Estimates Following Private Placement; Keeps Outperform Rating	Jan. 26	MT
Dianthus Therapeutics, Inc. announced that it expects to receive $229.997318 million in funding	Jan. 21	CI
Jefferies Initiates Dianthus Therapeutics at Buy With $22 Price Target	Dec. 26	MT
Dianthus Therapeutics, Inc. Announces Executive Appointments	Nov. 29	CI
Wedbush Starts Dianthus Therapeutics With Outperform Rating, $23 Price Target; Sees DNTH103 as Promising Candidate	Nov. 22	MT
Raymond James Starts Dianthus Therapeutics at Outperform, $24 Price Target	23-09-28	MT
Dianthus Therapeutics, Inc. announced that it has received $71.987749 million in funding from a group of investors	23-09-10	CI

Chart Dianthus Therapeutics, Inc.

Duration

Period

More charts

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Dianthus Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.81 USD

Average target price

50.17 USD

Spread / Average Target

+110.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DIANTHUS THERAPEUTICS, INC.	+128.94%	699M
VERTEX PHARMACEUTICALS INCORPORATED	+2.87%	108B
REGENERON PHARMACEUTICALS, INC.	+10.28%	105B
ARGENX SE	+1.57%	23.46B
BIONTECH SE	-12.17%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-37.64%	17.45B
BEIGENE, LTD.	-6.65%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+6.26%	13.99B
SAREPTA THERAPEUTICS, INC.	+36.87%	12.53B

Bio Therapeutic Drugs

Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

Biotechnology & Medical Research

Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc

Latest news about Dianthus Therapeutics, Inc.

Chart Dianthus Therapeutics, Inc.

Company Profile

Income Statement Evolution

Ratings for Dianthus Therapeutics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs